Komori
Share Issuance and Disposal4583Chiome Bioscience Inc.Pharmaceuticals

Notice Concerning the Large-Scale Exercise of the 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause)

A total of 14,562 of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) were exercised between 1 April 2026 and 27 April 2026, and 1,456,200 new shares were issued. The unexercised balance decreased from 90,125 to 75,563 rights.

Worth reading
30Immaterial
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1456200
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Significant exercise of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

1,456,200 new shares (from 1 April 2026 to 27 April 2026)

Terms of the stock acquisition rights
Exercise price
Exercise price adjustment clause included. Exercise price: ¥92.0–¥95.7 (actual exercise prices during the period). Floor price adjustment: Not disclosed
Number of Stock Acquisition Rights
Total number issued: 135,?00 rights (14,562 exercised, or 10.70% of the total number issued); unexercised balance at the end of the previous month: 90,125 rights; current unexercised balance: 75,563 rights. The exact total number issued: Not disclosed
Most recent equity financing
Timing 15 December 2025 / Type Issuance of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalSignificant exercise of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed of1,456,200 new shares (from 1 April 2026 to 27 April 2026)
Exercise priceExercise price adjustment clause included. Exercise price: ¥92.0–¥95.7 (actual exercise prices during the period). Floor price adjustment: Not disclosed
Number of Stock Acquisition RightsTotal number issued: 135,?00 rights (14,562 exercised, or 10.70% of the total number issued); unexercised balance at the end of the previous month: 90,125 rights; current unexercised balance: 75,563 rights. The exact total number issued: Not disclosed
Most recent equity financingTiming 15 December 2025 / Type Issuance of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) / Amount Not disclosed
Items this document does not state (23)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company does not state a reason.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Large-Scale Exercise of the 23rd Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) | Chiome Bioscience Inc. (4583) timely disclosure | Komori